Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12778161 | 0.95 | PTGDR2 (0.38) | PTGDR2KCNH2ALDH1A1GAACYP2C9 | |
| SCHEMBL12778167 | 0.94 | LMNA (0.38) | KCNH2ALDH1A1GAACYP2C9LMNA | |
| SCHEMBL12778150 | 0.91 | KCNH2 (0.36) | KCNH2ALDH1A1GAACYP2C9LMNA | |
| SCHEMBL12778158 | 0.91 | GNRHR (0.36) | KCNH2ALDH1A1GAACYP2C9LMNA | |
| SCHEMBL12778165 | 0.90 | LMNA (0.38) | KCNH2ALDH1A1GAACYP2C9LMNA | |
| SCHEMBL12778156 | 0.90 | KCNH2 (0.35) | KCNH2ALDH1A1GAACYP2C9LMNA | |
| SCHEMBL14530340 | 0.90 | KCNH2 (0.34) | KCNH2ALDH1A1GAACYP2C9LMNA | |
| SCHEMBL12778157 | 0.90 | PKM (0.40) | KCNH2ALDH1A1GAACYP2C9LMNA | |
| SCHEMBL12778155 | 0.89 | KCNH2 (0.39) | KCNH2ALDH1A1GAACYP2C9LMNA | |
| SCHEMBL12778172 | 0.89 | KCNH2 (0.35) | KCNH2ALDH1A1GAACYP2C9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902182-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902182-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| WO-2007059229-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070111985-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-17 | — | — | US | disclosed |
| US-20070111985-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111985-A1 | HIV integrase inhibitors | TYMP, POLN, IMPDH1 | PTGDR2 2864/4885KCNH2 3129/4885ALDH1A1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.